Dr David Okonji is a Medical Oncologist at Wellington Hospital in New Zealand, who is researching into metastatic breast cancer, asking the question: Are we curing HER+ Metastatic Breast Cancer? He was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting, and we asked Dr Okonji to explain his research on this topic ..read more

Associate Professor Lesley Stafford is a clinical psychologist in psycho-oncology and women's health, with a specific interest in women with or at risk of breast cancer. She consults in the Breast Service and Familial Cancer Centre at the Royal Melbourne Hospital as well as in private practice, and is an Associate Professor at the University of Melbourne ..read more

Dr Shom Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre, with a strong interest in Translational Breast Cancer Research. He was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting and we asked Dr Goel to explain his research in CDK4/6 inhibitors and where research is going in the future ..read more

As part of a Clinical Fellowship project with Breast Cancer Trials, Dr Christine Muttiah is aiming to assist in the clinical conduct of the BRCA-P study in the hopes to increase recruitment across all 14 Breast Cancer Trials BRCA-P sites. We asked Dr Muttiah to provide an overview of this project and its aims ..read more

While there is no way to prevent breast cancer, there are steps that can be taken to lower one's risk of being diagnosed, particularly for women with a strong family history or those who carry a gene mutation. Dr Wanda Cui is a Medical Oncologist at the Peter MacCallum Cancer Centre and is researching into breast cancer prevention within the risk management clinic. We asked Dr Cui to explain her research on Breast Cancer Prevention ..read more

Professor Prue Francis is a Medical Oncologist and the Clinical Head of Breast Medical Oncology at the Perter McCallum Cancer Centre. Professor Francis is researching into Metastatic breast cancer, asking the question: Does Detecting Metastatic Disease Early Make a Difference? We asked Professor Francis to explain her research on this topic ..read more

Dr Hope Rugo is a Professor of Medicine in the Division of Hematology and Oncology at the University of California, San Francisco. Dr Rugo is a Principal Investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment. We asked Dr Rugo to explain her research topic: New Options in HR+ Breast Cancer - TROPICS-02 and beyond ..read more

Health economics is used in clinical trials to ensure information is being collected in the right way, so that it can be provided to the minister or committees such as the Pharmaceutical Benefits Advisory Committee, so that they can compare new treatments with existing treatments to decide what drugs should be funded in the public system. We asked Associate Professor De Abreu Lorenco to explain what health economics is, and how it is currently used in clinical trials ..read more

Radiation therapy after breast conserving surgery plays an important role in the management of early breast cancer, decreasing the risk of breast cancer returning and improving mortality rates. Dr Janice Yeh is evaluating the technical feasibility and clinical performance of the novel NASHA gel compared to standard surgical clips as a fiducial marker ..read more

Katharine and Skye had never met each other, but they shared something in common. Both women carry the BRCA-1 gene mutation. This is an inherited gene which increases their chance of developing breast cancer by 70% and ovarian cancer by 40% throughout their lifetime. Until now, life-changing invasive surgery and regular breast screening have been the only options available for women like Katharine and Skye. However, the BRCA-P clinical trial aims to open up a new treatment opportunity for women with this gene mutation. BRCA-P is a preventative trial, which is testing the effectiveness of a dru ..read more